Genmab A+s

Genmab B.v.

Janssen Biotech, Inc.

Biontech Se

Janine Schuurman

Paul Parren

Aran Frank Labrijn

Jan Van De Winkel

Joost J Neijssen

Joyce Meesters

Ole Baadsgaard

Edward Norbert Van Den Brink

Jan G J Van De Winkel

Bart De Goeij

Tom Vink

Arnout F Gerritsen

Patrick Van Berkel

Frank Beurskens

Jørgen Petersen

Rene Hoet

Rob N De Jong

Rik Rademaker

Denise Leah Williams

Mark Chiu

Marcus A Van Dijk

Catharina Emanuele Gerarda Havenith

Ewald T J Van Den Bremer

David Satijn

Isil Altintas

Sheri Moores

Joost Neijssen

Kristin Strumane

Esther Breij

Marije Overdijk

Willem Karel Bleeker

Simone De Haij

Thilo Riedl

Bart-Jan De Kreuk

Richard Hibbert

Rob Aalberse

Ugur Sahin

Sandra Verploegen

Alexander Muik

Michael J Gramer

Patrick Engelberts

Stefan Loverix

Esther Cornelia Wilhelmina Breij

Sina Fellermeier-kopf

Lars Guelen

Amitava Kundu

Muriel Van Kampen

Patrick Priem

Werner L Vos

Marijn Van Der Neut Kolfschote

Jan G Van De Winkel

Ewald Van Den Bremer

Jan Van Winkel

Yvo Graus

Friederike Gieseke

Ignace Lasters

Adam Zwolak

Thomas C Nesspor

Simone Oostindie

Riemke Van Dijkhuizen Radersma

Anthony A Armstrong

David P E Satijn

Marijn Van Der Neut Kolfschoten

Jorgen Petersen

Karsten Beckmann

Claudia Paulmann

Ivan Kuzmanov

Patricia Garrido Castro

Jordan Blum

Andreea Ioan

Annieck M Diks

Kristina Nürmberger

Rene M A Hoet

Mario Losen

Pilar Martinez-Martinez

Marc H De Baets

Matthew Bunce

Jau Van De Winkel

Lgnace Laster

Arjen Vlug

Jørgen Peterson

Richard G Hibbert

Rene M Hoet

Marcus Antonius Van Dijk

Ole D Baadsgaard

Catharina Emanuele Havenith

Aran Labrijn

Edward N Brink

Marijn Van Kolfschoten

Ewald Van Bremer

Joyce I Meesters

René Hoet

The present invention provides a binding agent that binds to EpCAM and to CD137 which is useful to treat or prevent a tumor or cancer, or to prevent progression of a tumor or cancer.

Binding agents binding to EpCAM and CD137

Provided herein are combinations of first and second antibodies having modified Fc effector functions resulting from amino acid substitutions in the Fc region, the amino acid substitutions allow for co-dependent activation of effector functions such as CDC and/or ADCC. Also provided are combinations of first and second antibodies having agonistic activity or enhanced agonistic activity resulting from amino acid substitutions in the Fc region where the agonistic activity is co-dependent of both a first and second antibodies.

Antibody variant combinations and uses thereof

The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signalling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

Anti-DR5 antibodies and methods of use thereof

Bispecific EGFR/c-Met antibodies and methods of making and using the molecules.

Bispecific EGFR/c-Met antibodies

The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.

Method for producing a controlled mixture of two or more different antibodies

As described herein are polypeptides and antibodies having an Fc region and an antigen binding region where the Fc region has an Fc-Fc-enhancing mutation and a C1q binding-enhancing mutation providing for polypeptides or antibodies with increased CDC activity and/or agonistic activity.

Polypeptide variants and uses thereof

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc:Fc interactions when the polypeptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved effector functions, such as CDC-response.

Antibody variants and uses thereof

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.

Humanized or chimeric CD3 antibodies

Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed.

Bispecific antibodies against HER2 and CD3

Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

Monoclonal antibodies against c-Met

The present invention relates to an in vitro method for production of heterodimeric proteins.

Production of heterodimeric proteins

Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

Inert format

Growing community of inventors

Diemen, Netherlands

Janine Schuurman